PSMA has become a target for PCa imaging. Initially, ProstaScint, an indium labelled PSMA antibody was introduced clinically, but it was the advent of small urea based PSMA targeting peptides that has transformed PCa imaging. The introduction of 68Ga-PSMA-11 at the University of Heidelberg in 2013 led to an explosion of evidence demonstrating the superiority of PSMA-PET agents over tracers such as Fluoromethyl-choline and Fluciclovine.1, 2, 3, 4 Within a decade, PSMA-PET is now funded in many countries for initial staging and biochemical recurrence of PCa, although it requires more evidence for its use in diagnosis and treatment response to systemic therapies. Our knowledge of its value as an imaging biomarker with prognostic and predictive value in improving personalization of treatment choices is growing. To optimize its potential as a biomarker, we need to ensure that PSMA-PET reports clearly delineate important findings to the clinician, pertinent to the patient's clinical context. Reports need to be tailored to the stage of PCa and answer relevant clinical questions for the clinician to improve patient outcomes and minimize uncertainty.